Thrombus prevention

Modification of Graft Surface for Clot (Thrombus) Prevention... 

Oxagrelate (104) is of interest as a platelet antiaggretory agent and is thus of potential value in preventing thrombus formation in blood vessels. It may also be of potential value in preventing arteriosclerotic lesions in coronary arteries - a substantial cause of morbidity and mortality in... 

Due to the pivotal role of platelets in thrombus formation, especially in the arterial system, inhibition of platelet function has become a central pharmacological approach. Antiplatelet drugs are given in order to prevent and treat thromboembolic diseases such as coronary heart disease, peripheral and cerebrovascular disease. They have also revolutionized the procedures of invasive coronary interventions as they reduce the risk of restenosis and thrombosis. 

Summarizing the fibrinolytic therapy, it should be emphasized that efficient treatment needs urgent application of plasminogen activator (within a few hours) to prevent the formation of crosslinks in the fibrin structure (Fig. 2) and to find the localization of thrombus to emerge plasmin on the surface of fibrin to prevent rapid inactivation of the enzyme by the inhibitor system of fibrinolysis (Fig. 3). 

Thrombosis is the development of a thrombus , consisting of platelets, fibrin, red and white blood cells in the arterial or venous circulation. Platelet-rich white thrombi are found in the arterial system and can be prevented by antiplatelet drugs. 

Prevention of thrombus formation after valve replacement... 

It is also important that the nurse monitor for any indication of hypersensitivity reaction. The nurse reports reactions, such as chills, fever, or hives, to die primary health care provider. When heparin is given to prevent the formation of a thrombus, the nurse observes the patient for signs of thrombus formation every 2 to 4 hours. Because the signs and symptoms of dirombus formation vary and depend on the area or organ involved, die nurse should evaluate and report any complaint die patient may have or any change in die patient s condition to die primary health care provider. 

Heparin may be given along with and/or after administration with a thrombolytic drug to prevent another thrombus from forming. However, administration of an anticoagulant increases the risk for bleeding. The patient must be monitored closely for internal and external bleeding. 

Acute anticoagulation is widely used in the acute setting of arterial dissection. Once again, the rationale is to prevent propagation of local thrombosis and formation of new thrombus at the site of the injured arterial wall, which is beheved to reduce the likelihood of early stroke recurrence. This practice, while rational, is based on anecdotal evidence and case series, as randomized controlled trials have... 

UFH prevents the growth and propagation of a formed thrombus and allows the patient s own thrombolytic system to degrade the clot. 

ICAM-1, ICAM-2) and vascular cell adhesion molecule (VCAM). Platelets are attracted to damaged endothelium where they adhere to prevent blood loss in a similar fashion to white blood cells, i.e. via adhesion molecule interactions, to form a clot (thrombus). 

Lotrafiban, a nonpeptidic glycoprotein llb/llla receptor anagonist that was under development as a treatment for the prevention of platelet aggregation and thrombus formation, was initially prepared using an 11-step linear sequence starting from methyl Cbz-L-aspartate (Scheme 1.35). An overall yield of 9 % and issues with obtaining the product in sufficient enantiopurity led the group to look for an alternative route via the enzymatic... 

The normal endothelial cells possess characteristics that prevent thrombus formatiou iudeed, their surface is one of the few that has such properties. Three of these characteristics are ... 

Bilberry Vaccinium myrtillus) Uses Prevent/treat visual problems such as cataract, retinopathy, myopia, glaucoma, macular degeuCTation treat vascular problems such as hemorrhoids, varicose veins Actions Contains anthocyanidin that X vascular permeability, inhibit pit aggregation thrombus formation, t antioxidant effects on LDLs liver, t regeneration of rhodopsin... 

Arterial thrombi (white thrombi) are formed initially from both platelets and fibrin in medium-sized arteries on the basis of atherosclerosis. These thrombi can lead to symptoms of, among others, myocardial ischemia and myocardial infarction. The treatment is primarily aimed at prevention of thrombus formation with platelet aggregation inhibitors. For the treatment of myocardial infarction thrombolytic agents are used and for secondary prevention both oral anticoagulants and anti-platelet drugs are employed. 

Use of heparin and heparinoids is aimed at inhibiting thrombus propagation into large and small vessels and prevent arterial (and venous) re-embolisation. Very few clinicians use this approach, at least for the time being. 

Mechanism of Action An aggregation inhibitor that inhibits the release of adenosine diphosphate from activated platelets, which prevents fibrinogen from binding to glycoprotein Ilb/IIIa receptors on the surface of activated platelets. TherapeuticEffect Inhibits platelet aggregation and thrombus formation. 

Mechanism of Action An antiplatelet and antithrombotic agent that binds to platelet receptorglycoproteinllb/Illa, preventing binding of fibrinogen. Therapeutic Effect inhibits platelet aggregation and thrombus formation. 

Effect on blood Platelets are the important factors in thrombus formation and aspirin has been shown to inhibit platelet aggregation. They reduce the blood prothrombin level by inhibition of prothrombin synthesis and prothrombin time is prolonged. The aspirin suppresses the synthesis of thromboxane (TXA ) in the platelets. They also prolong the bleeding time due to prevention of platelet aggregation which may be due to inhibition of release of adenosine diphosphate (ADP) from the platelets by salicylates. 

As antiplatelet agent By inhibiting platelet aggregation aspirin may lower the incidence of reinfarction. It has been used to prevent the formation of platelet-fibrin thrombus in ischemic heart disease patients. 

Streptokinase is a protein (but not an enzyme in itself) synthesized by streptococci that combines with the proactivator plasminogen. This enzymatic complex catalyzes the conversion of inactive plasminogen to active plasmin. Urokinase is a human enzyme synthesized by the kidney that directly converts plasminogen to active plasmin. Plasmin itself cannot be used because naturally occurring inhibitors in plasma prevent its effects. However, the absence of inhibitors for urokinase and the streptokinase-proactivator complex permits their use clinically. Plasmin formed inside a thrombus by these activators is protected from plasma antiplasmins, which allows it to lyse the thrombus from within. 

Most drug discovery efforts focus on thrombin inhibition as a means to prevent the serious consequences of thrombus formation in myocardial infarction and stroke. Thrombin inhibitors may also prevent clot formation in patients prone to deep vein thrombosis or repeat heart attack. In combination with thrombus dissolution therapies, thrombin inhibitors may decrease the incidence of reocclusion due, in part, to the release of active clot-bound thrombin. 

Prompt administration of intravenous heparin is indicated in the treatment of this condition. Heparin is fast-acting, prevents furlher thrombus formation, and when used in therapeutic doses, also prevents the release of serotonin and thromboxane A from platelets that adhere to thrombi that embohze to the lungs. The size of file dose required varies with a number of patient conditions. Several authorities are convinced that file continuous (pump-driven) infusion method is superior to intermittent injections. 

---